2018•Unpublished venueRequires access

Progress of related diseases features and prognostic evaluation of myelodysplastic syndromes

Jie Yang

Abstract

Myelodysplastic syndromes (MDS) characterized by the presence of ineffective hematopoiesis and an increased risk of transformation to acute myeloid leukemia (AML), is a group of clonal disorders deriving from the hematopoietic stem/progenitor cells. The 59th American Society of Hematology (ASH) Annual Meeting introduced detailed reports on disease genes, the molecular mechanism, therapeutic targets, new drugs and clinical research of MDS. Combined with reports in the 59th ASH Annual Meeting, this article summarizes the latest progress of the related diseases features and prognostic evaluation of MDS. Key words: Myelodysplastic syndromes; Characteristics; Prognostic evaluation

About this research paper

What this paper is about

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Myelodysplastic syndromes, Myeloid leukemia, Medicine, Hematology, Oncology, Internal medicine, Haematopoiesis, Disease